Title:Vanadium Complexes with Hydrazone or Thiosemicarbazone Ligands as Potential Anti-Mycobacterium tuberculosis Agents
Volume: 10
Issue: 1
Author(s): Paula C. de Souza, Pedro I. S. Maia, Heloisa B. de Barros, Clarice Q. F. Leite, Victor M. Deflon and Fernando R. Pavan
Affiliation:
Keywords:
Dioxovanadium(V), hydrazone, Mycobacterium tuberculosis, new antituberculosis compounds, thiosemicarbazone.
Abstract: Tuberculosis (TB) is an infectious disease caused mainly by Mycobacterium tuberculosis
(MTB) and still an important public health problem worldwide. Some factors like the emergence of
multidrug resistant (MDR) and extensively drug-resistant (XDR) strains make urgent the research of
new active compounds. Searching for new inorganic compounds against TB, three new dioxovanadium(V)
complexes were obtained upon reaction of [VO(acac)2] with hydrazone and thiosemicarbazone
ligands derived from di-2-pyridyl ketone. Spectroscopic studies and X-ray crystallography revealed
asymmetrically oxo bridged binuclear complexes of the type [{VO(L1,2)}2(μ-O)2], involving the
hydrazone ligands, while a mononuclear square pyramidal complex of the type [VO2(L3)] was formed with the
thiosemicarbazone ligand. The compounds were tested against M. tuberculosis and three of them, with MICs values
between 2.00 and 3.76 μM were considered promising for TB treatment. Such MIC values are comparable or better than
those found for some drugs currently used in TB treatment.
